Chlamydia psittaci in Pet Birds: Zoonotic Transmission and Diagnostic Approaches

Introduction

The obligate intracellular bacterium Chlamydia psittaci is the causative agent of avian chlamydiosis (psittacosis) and represents a significant zoonotic pathogen transmitted from pet birds to humans [1, 2]. The organism belongs to the family Chlamydiaceae, which includes several species that infect a wide range of hosts. C. psittaci is characterised by a biphasic developmental cycle alternating between infectious elementary bodies (EBs) and metabolically active reticulate bodies (RBs) [3]. Based on outer membrane protein A (OmpA) genotyping, the species is divided into multiple genotypes (A through F, and others) that exhibit varying degrees of host tropism and virulence. Genotype A is predominantly associated with psittacine birds and is the most common cause of human psittacosis, whereas genotypes B and C are more frequently found in pigeons and ducks, respectively [4, 5]. In the pet bird setting, psittacines (parrots, cockatiels, budgerigars) and columbiforms (pigeons, doves) are primary reservoirs.

Pathogenesis in Birds

Infection occurs via inhalation or ingestion of aerosolised dried feces, respiratory secretions, or feather dust containing EBs [6]. EBs attach to epithelial cells of the upper respiratory tract and conjunctiva via receptor-mediated endocytosis. Within the host cell, the EB differentiates into the RB, which replicates within a membrane-bound inclusion body [7]. The RB undergoes binary fission for 24 to 48 hours, then redifferentiates back into EBs, which are released by cell lysis or extrusion, propagating the infection to adjacent cells [3, 8].

Systemic dissemination follows initial replication in the respiratory epithelium. The bacteria travel via mononuclear phagocytes to the liver, spleen, and air sacs, causing focal necrosis, hepatomegaly, splenomegaly, and airsacculitis [9]. In severe cases, pericarditis, peritonitis, and encephalitis may occur. The clinical outcome ranges from acute fatal disease to subclinical persistent infection. Carrier birds may shed organisms intermittently, especially under stress [10].

Shedding Routes and Zoonotic Transmission

Infected birds shed C. psittaci in high concentrations in feces, ocular exudates, nasal discharge, and feather dust [11]. Dried fecal material can remain infectious for several months, facilitating airborne transmission [12]. Humans acquire psittacosis primarily by inhaling aerosolised dried excreta or respiratory secretions from infected birds, but also by direct contact with infected tissues or mouth-to-beak contact [2, 13]. Occupational exposure is a well recognised risk for pet shop employees, avian veterinarians, and bird owners [14]. The infectious dose for humans is low; even brief exposure to an asymptomatically shedding bird can lead to infection [15].

Zoonotic transmission of C. psittaci from pet birds is a persistent public health concern. The disease in humans, known as psittacosis or ornithosis, typically manifests as an influenza-like illness with fever, headache, and non-productive cough that can progress to severe pneumonia [16]. While this reference article does not discuss human clinical management, understanding the transmission dynamics is critical for veterinary professionals to implement biosecurity measures and diagnostic testing. The parallels between zoonotic C. psittaci and other avian bacterial zoonoses, such as those described in Salmonella enterica Serovar Typhimurium in Backyard Poultry Flocks, underscore the importance of routine screening in companion birds.

Clinical Signs in Pet Birds

The clinical presentation of avian chlamydiosis varies with host species, age, immune status, and bacterial genotype [17]. In acute cases, affected birds exhibit lethargy, anorexia, ruffled feathers, dyspnea, conjunctivitis, and yellow-green diarrhoea. Ocular and nasal discharges are common. Mortality can be high, particularly in young budgerigars and cockatiels [18]. Subacute disease presents with more gradual weight loss, sinusitis, and respiratory distress. Chronic or asymptomatic carriers show intermittent shedding and may develop secondary bacterial infections [19].

A key diagnostic challenge is that subclinically infected birds appear outwardly healthy yet continue to shed organisms. Stressors such as relocation, breeding, or concurrent disease can trigger overt shedding and clinical disease [10].

Diagnostic Approaches

Accurate diagnosis of C. psittaci infection in pet birds relies on a combination of clinical assessment, cytology, serology, and molecular methods. The choice of sample type and assay directly affects sensitivity and specificity.

Sample Collection

Chlamydial shedding is intermittent, and multiple specimens improve detection. The gold standard for antemortem diagnosis is a combined choanal and cloacal swab (CCS) [20]. Oropharyngeal swabs yield higher sensitivity than conjunctival swabs. Fecal samples alone are less reliable due to bacterial inhibitors and lower organism load [21]. Postmortem diagnosis uses impression smears and homogenates of liver, spleen, and air sac tissue.

Swab transport medium should be chlamydia transport medium or universal transport medium; improper storage (e.g., cotton swabs with wooden shafts) can inhibit PCR due to residual PCR inhibitors [22].

Nucleic Acid Amplification Tests (NAAT)

Real-time polymerase chain reaction (PCR) targeting the ompA gene or the 16S rRNA gene is the most sensitive and specific diagnostic platform [23, 24]. PCR can detect as few as 10 genome copies per reaction and can differentiate C. psittaci from other Chlamydiaceae species through melt curve analysis or probe hybridisation [25]. Multiplex PCR panels have been developed that simultaneously detect C. psittaci, mycoplasmas, and other avian respiratory pathogens [26].

The specificity of PCR exceeds that of serology because it detects bacterial DNA rather than antibody, which may persist after clearance [27]. False negatives may occur if the swab does not contain viable organisms, but the assay can detect non-viable EBs, making it suitable for screening clinically normal carriers [28].

Serology

Serological tests detect antibodies (IgY) against C. psittaci. The complement fixation test (CFT) was historically standard but has been largely replaced by enzyme-linked immunosorbent assays (ELISAs) using recombinant antigens [29]. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus provides a methodological parallel for protein antigen detection; analogous indirect ELISAs are used for avian chlamydiosis. However, seroconversion may take 10 to 14 days, and immunosuppressed birds may not mount a detectable response [30]. Cross-reactivity among Chlamydiaceae species complicates interpretation [31]. Serology is therefore best used for herd screening rather than individual diagnosis.

Cytology and Culture

Impression smears from conjunctiva, choana, or feces can be stained with modified Gimenez stain or a direct immunofluorescent antibody (DFA) test to visualise EBs [32]. Cytology has low sensitivity (30-50%) and requires experienced microscopists [33]. Chlamydial culture in cell lines (e.g., McCoy, BGM) is highly specific but slow (3-7 days) and requires biosafety level 3 containment due to the zoonotic risk [34]. Culture is rarely used in first-line diagnostics.

Diagnostic Algorithm

A recommended diagnostic workflow is outlined below. The decision tree integrates clinical presentation, risk assessment, and confirmatory testing.

flowchart TD
    A[Bird with clinical signs or exposure risk], > B[Collect combined choanal/cloacal swab]
    B, > C{Perform real-time PCR}
    C, >|Positive| D[Confirm with ompA genotyping if needed]
    C, >|Negative but high suspicion| E[Repeat swab in 2-3 weeks]
    E, > F[Consider serology for chronic infection]
    D, > G[Initiate doxycycline treatment]
    G, > H[Follow-up PCR after treatment course]
    F, > I[If seropositive without PCR confirmation, treat empirically]
    H, > J[Clearance confirmed: two consecutive negative PCRs 2 weeks apart]

Treatment Protocols

Doxycycline is the drug of choice for avian chlamydiosis [35]. It is a bacteriostatic tetracycline that inhibits protein synthesis by binding to the 30S ribosomal subunit. The recommended dosage is 25-50 mg/kg orally for 45 days. Medicated feed formulations containing doxycycline at 1 g/L of drinking water are used for flock treatment, but water intake is variable [36]. Injectable doxycycline (50 mg/kg IM weekly for 4-6 weeks) is an alternative for individual birds but may cause injection-site reactions [37]. Doxycycline should be dosed cautiously in small psittacines to avoid hepatotoxicity.

Treatment duration is crucial; a minimum of 30 days is required due to the slow replication cycle of C. psittaci and the necessity to eliminate persistent infections. Short courses may lead to relapse or emergence of antimicrobial resistance [38]. Enrofloxacin and azithromycin have been used but are less effective and are not recommended as first-line agents [39].

Antimicrobial Resistance and Biosecurity

The emergence of tetracycline resistance in C. psittaci strains has been reported in poultry and pet bird populations, though prevalence remains low [40]. Resistance mechanisms include acquisition of the tetracycline resistance gene tet(C) [41]. Routine susceptibility testing is not widely available, so treatment failure should prompt resistance analysis. The parallel concerns regarding antimicrobial resistance in livestock-associated bacteria are discussed in Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus.

Biosecurity measures include quarantine of new birds for 30-60 days, screening with PCR before introduction, and wearing protective equipment (N95 mask, gloves) when handling suspect birds [42]. Environmental decontamination with quaternary ammonium compounds or 1% bleach solution inactivates EBs on surfaces [43].

Human Exposure Risk in the Veterinary Setting

Veterinary personnel are at heightened risk for psittacosis. The incubation period in humans is 5-14 days, and respiratory illness can be severe. Aerosol-generating procedures (nebulization, wound irrigation with high-pressure devices) should be avoided in infected birds [44]. When a zoonotic case is suspected, the veterinary clinic should report to public health authorities [45]. The risk assessment parallels that of other airborne zoonoses such as Avian Influenza A(H5N1) in Poultry and Wild Birds, where screening and barrier precautions are equally critical.

Future Directions

Improvements in point-of-care molecular diagnostics may eventually allow rapid antigen detection using lateral flow assays or isothermal amplification methods [46]. Metagenomic sequencing of swab samples can identify mixed infections with other avian pathogens [47]. Bioinformatics approaches, such as genome-wide association studies, are being applied to understand host adaptability and virulence determinants of C. psittaci [48, 49]. Additionally, vaccine development for avian chlamydiosis remains an area of active investigation; recombinant subunit vaccines based on the major outer membrane protein (MOMP) have shown partial protection in experimental models [50].

Conclusion

Chlamydia psittaci remains a formidable pathogen in pet bird populations, capable of causing clinical and subclinical infections with significant zoonotic potential. Accurate diagnosis relies on PCR of combined choanal and cloacal swabs, supported by serology and cytology where appropriate. Doxycycline administered over 30-45 days remains the cornerstone of treatment. Veterinary professionals should implement rigorous biosecurity and diagnostic screening to protect both avian patients and human contacts. Continued surveillance for antimicrobial resistance and the development of rapid diagnostic tools will enhance the management of this persistent zoonotic threat.

References

[1] Longbottom D, Coulter LJ. Animal chlamydioses and zoonotic implications. Journal of Comparative Pathology.

[2] Harkinezhad T, Geens T, Vanrompay D. Chlamydophila psittaci infections in birds: a review with emphasis on zoonotic consequences. Veterinary Microbiology.

[3] Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiological Reviews.

[4] Geens T, Deschacht N, Vanrompay D. Molecular characterization of Chlamydia psittaci strains from domestic pigeons. Avian Pathology.

[5] Vanrompay D, Butaye P, Sayada C, Ducatelle R, Haesebrouck F. Characterization of avian Chlamydia psittaci strains using ompA restriction mapping. International Journal of Systematic Bacteriology.

[6] Andersen AA. Avian chlamydiosis. Journal of Avian Medicine and Surgery.

[7] Hackstadt T. The diverse habitats of obligate intracellular parasites. Current Opinion in Microbiology.

[8] Wyrick PB. Intracellular survival by Chlamydia. Methods in Enzymology.

[9] Grimes JE, Phalen DN. Chlamydiosis in birds: diagnosis, treatment, and control. Seminars in Avian and Exotic Pet Medicine.

[10] Gerlach H. Chlamydiosis in companion birds. Veterinary Clinics of North America: Small Animal Practice.

[11] Harkinezhad T, Verminnen K, Van Droogenbroeck C, Vanrompay D. Chlamydophila psittaci genotype B infections in racing pigeons: experimental infection and transmission. Avian Pathology.

[12] Vanrompay D, Harkinezhad T, van de Walle M, Beeckman D, van Droogenbroeck C, Verminnen K, et al. Chlamydophila psittaci transmission from pet birds to humans. Emerging Infectious Diseases.

[13] Beeckman DSA, Vanrompay DCG. Zoonotic Chlamydophila psittaci infections from a clinical perspective. Clinical Microbiology and Infection.

[14] Williams J, Tallis G, Dalton C, Ng S, Beaton S, Catton M, et al. Community outbreak of psittacosis in a rural Australian town. The Lancet.

[15] Moroney JF, Guevara R, Iverson C, Chen FM, Skelton SK, Messmer TO, et al. Detection of chlamydiosis in a shipment of pet birds, leading to recognition of an outbreak of clinically mild psittacosis in humans. Clinical Infectious Diseases.

[16] Smith KA, Bradley KK, Stobierski MG, Tengelsen LA. Compendium of measures to control Chlamydophila psittaci infection among humans (psittacosis) and pet birds, 2005. Journal of Veterinary Internal Medicine.

[17] Schedel M, Hafez HM. Chlamydophila psittaci infections in pet birds: prevalence and diagnostic methods. Tierärztliche Praxis.

[18] Stenzel T, Pestka D, Chrzastek K, Koncicki A. Prevalence and antibiotic susceptibility of Chlamydia psittaci in pet birds in Poland. Polish Journal of Veterinary Sciences.

[19] Dickx V, Vanrompay D. The avian as a reservoir of Chlamydia psittaci: an underestimated zoonotic risk. Veterinary Journal.

[20] Vanrompay D, Ducatelle R, Haesebrouck F. Diagnosis of avian chlamydiosis: specificity of the modified Gimenez staining on smears and comparison of the sensitivity of isolation in eggs and two different cell culture systems. Journal of Veterinary Medicine, Series B.

[21] Messmer TO, Skelton SK, Moroney JF, Daugharty H, Fields BS. Application of a nested, multiplex PCR to psittacosis outbreaks. Journal of Clinical Microbiology.

[22] Sachse K, Hotzel H. Detection and differentiation of Chlamydiae by nested PCR. Methods in Molecular Biology.

[23] Ehricht R, Slickers P, Goellner S, Hotzel H, Sachse K. Optimized DNA microarray assay allows detection and genotyping of single PCR-amplifiable target from Chlamydia trachomatis and Chlamydophila psittaci. Journal of Clinical Microbiology.

[24] Pantchev A, Sting R, Bauerfeind R, Tyczka J, Sachse K. New real-time PCR tests for species-specific detection of Chlamydophila psittaci and Chlamydophila aborti from tissue samples. Veterinary Journal.

[25] Geens T, Deschacht N, Vanrompay D. Application of a multiplex PCR assay for the simultaneous detection of Chlamydophila psittaci, Chlamydophila abortus, and Chlamydia trachomatis in clinical samples. Journal of Clinical Microbiology.

[26] Cattoli G, De Battisti C, Toffan A, Monne I, Capua I. A sensitive one-step real-time PCR for detection of avian influenza virus and for simultaneous detection of Mycoplasma spp. and Chlamydophila psittaci in clinical samples. Avian Pathology.

[27] Sachse K, Grossmann E, Berndt A, Soutschek E. Detection of Chlamydia psittaci in birds by PCR and direct immunofluorescence. Journal of Veterinary Medicine, Series B.

[28] Vanrompay D, Ducatelle R, Haesebrouck F, Hendrickx W. Diagnosis of avian chlamydiosis: comparison of serology, isolation, and DNA probe techniques. Avian Pathology.

[29] Souriau A, Rodolakis A. Evaluation of an ELISA for the detection of anti-Chlamydia antibodies in birds. Veterinary Microbiology.

[30] Wittenbrink MM, Bisping W, Failing K. Serological investigations in avian chlamydiosis: comparative studies of complement fixation test and ELISA. Zentralblatt für Veterinärmedizin Reihe B.

[31] Salinas J, Souriau A, Cuello F, Rodolakis A. Serological survey of avian Chlamydia psittaci infection in Spain. Journal of Veterinary Medicine, Series B.

[32] Gimenez DF. Staining rickettsiae in yolk-sac cultures. Stain Technology.

[33] Dorrestein GM, Wiegman LJ, van der Hage MH. Comparison of two methods for the detection of Chlamydia psittaci in fecal samples of psittacine birds. Avian Pathology.

[34] Hatch TP. The biology of Chlamydia. Current Topics in Microbiology and Immunology.

[35] Fudge AM. Avian chlamydiosis: diagnosis and treatment. In: Harrison GJ, Lightfoot TL, editors. Clinical Avian Medicine. Spix Publishing.

[36] Wade LL, Ritch D. Comparison of oral and parenteral doxycycline therapy for avian chlamydiosis. Journal of Avian Medicine and Surgery.

[37] Flammer K. Treatment of chlamydiosis with doxycycline in psittacine birds. Journal of Avian Medicine and Surgery.

[38] Vanrompay D, Cox E, Mast J, Goddeeris B, Volckaert G. A vaccine against Chlamydia psittaci infection in birds: production of recombinant outer membrane protein and evaluation of its protective effect. Veterinary Immunology and Immunopathology.

[39] Butaye P, Ducatelle R, Haesebrouck F. In vitro activity of 13 antimicrobial agents against Chlamydia psittaci isolated from budgerigars. Journal of Veterinary Medicine, Series B.

[40] Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrobial Agents and Chemotherapy.

[41] Dugan J, Rockey DD, Jones L, Andersen AA. Tetracycline resistance in Chlamydia suis is mediated by a transposon-like element. Antimicrobial Agents and Chemotherapy.

[42] West A, Gustafson R, Kusalakumt P, Tschirgi D. Biosecurity practices for pet bird owners and avian veterinarians. Journal of Avian Medicine and Surgery.

[43] Harkinezhad T, Beeckman DSA, Vanrompay D. Chlamydia psittaci: a potential threat for pet bird owners and veterinarians. Veterinary Record.

[44] Smith KA, Bradley KK, Stobierski MG, Tengelsen LA. Compendium of measures to control Chlamydophila psittaci infection among humans (psittacosis) and pet birds, 2005. Journal of Veterinary Internal Medicine.

[45] Centers for Disease Control and Prevention. Outbreak of psittacosis in a group of women exposed to infected pet birds. Morbidity and Mortality Weekly Report.

[46] Wellinghausen N, Wösten A, Häck R, Marre R. Development of a real-time PCR for the detection of Chlamydia psittaci in clinical specimens. Journal of Medical Microbiology.

[47] Blooi M, Imberechts H, Deplano A, Struelens MJ, Vanrompay D. Metagenomic analysis of avian respiratory samples reveals a high diversity of Chlamydiaceae. Veterinary Microbiology.

[48] Seth-Smith HMB, Harris SR, Rance R, Persson K, Marsh P, Abdul-Majid KB, et al. Genome sequence of Chlamydia psittaci 6BC. Journal of Bacteriology.

[49] Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Research.

[50] Verminnen K, Van Loock M, Cox E, Goddeeris BM, Vanrompay D. Protection of turkeys against Chlamydophila psittaci challenge by DNA and recombinant MOMP vaccination. Vaccine.